Trial Profile
Pharmacokinetic and bioequivalence evaluation of single-tablet and separate-tablet regimens for once-daily cobicistat-boosted elvitegravir in healthy Japanese male subjects: A randomized, two-way crossover study.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 Nov 2015
Price :
$35
*
At a glance
- Drugs Elvitegravir (Primary) ; Cobicistat; Elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat; Emtricitabine/tenofovir disoproxil fumarate
- Indications HIV-1 infections
- Focus Pharmacokinetics
- Sponsors Japan Tobacco
- 26 Nov 2015 New trial record